Electra Therapeutics Presents Positive Clinical Results from Completed Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
ELA026 demonstrated 100% overall response rate, improved survival, and a favorable safety profile in malignancy-associated HLH (mHLH), the most common type of sHLH with the poorest prognosis. Company is advancing ELA026 as a frontline treatment for patients with sHLH and plans to initiate a global pivotal study in 2025…
Electra Therapeutics to Present Clinical Results for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in an Oral Session at ASH 2024
Data from completed Phase 1b study of ELA026 highlights results in patients with the poorest prognosis, those with malignancy-associated HLH SOUTH SAN FRANCISCO, CA, November 5, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today that clinical data for its lead […]
Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 has the potential to address a high unmet need for patients with a rare, life-threatening hyperinflammatory disease SOUTH SAN FRANCISCO, CA, November 4, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) […]
Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
ELA026 has the potential to address a high unmet need for patients with a rare, life-threatening hyperinflammatory disease SOUTH SAN FRANCISCO, CA, October 30, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) […]
Electra Therapeutics to Present Clinical Data for ELA026 in the Treatment of sHLH in an Oral Session at the 2024 Annual Meeting of the Histiocyte Society
Data from the Phase 1b Study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) highlights preliminary efficacy in patients with the poorest prognosis, those with malignancy-associated HLH SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today […]
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients and a favorable safety profile in this life-threatening hyperinflammatory condition In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival SOUTH SAN FRANCISCO, CA, June 16, 2024 – Electra Therapeutics, […]
Electra Therapeutics to Present ELA026 Clinical Data in Late-Breaking Oral Session at the 2024 European Hematology Association (EHA) Congress
Data from Phase 1b study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) to be presented on Sunday, June 16, 2024 SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical […]
Electra Therapeutics Builds Leadership Team with Appointment of Dr. Graham Parry as Chief Scientific Officer and Dr. Kim-Hien Dao as Chief Medical Officer
SOUTH SAN FRANCISCO, CA, June 3, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today the appointment of Graham Parry, PhD, as Chief Scientific Officer and Kim-Hien Dao, DO, PhD, as Chief Medical Officer. Both executives have deep […]
Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
ELA026 showed favorable safety and achieved overall response rate (ORR) of 70% in sHLH patients Majority of enrolled patients were in difficult-to-treat subtypes of sHLH associated with malignancies and relapsed/refractory disease SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases […]
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
Company expands board of directors and appoints Matthew Fust as independent director Building on positive clinical results for its lead antibody candidate, Electra is positioned to expand therapeutic opportunities in immunological diseases and cancer SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets […]
